Advertisement
Screener

INFUSYSTEM HOLDINGS, INC (INFU) Business Acquisition, Pro Forma Net Income (Loss)

INFUSYSTEM HOLDINGS, INC Business Acquisition, Pro Forma Net Income (Loss)

INFUSYSTEM HOLDINGS, INC (INFU) reported Business Acquisition, Pro Forma Net Income (Loss) of $1.94 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-16.

Discontinued › Expense Statement › Operating Expenses

us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2023-03-16

  • INFUSYSTEM HOLDINGS, INC business acquisition, pro forma net income (loss) for the quarter ending 2021-12-31 was $668.00K, a 93.56% decline year-over-year.
  • INFUSYSTEM HOLDINGS, INC business acquisition, pro forma net income (loss) for the quarter ending 2021-09-30 was -$373.00K, a 113.86% decline year-over-year.
  • INFUSYSTEM HOLDINGS, INC business acquisition, pro forma net income (loss) for the quarter ending 2021-06-30 was $1.00M, a 73.26% decline year-over-year.
  • INFUSYSTEM HOLDINGS, INC business acquisition, pro forma net income (loss) for the quarter ending 2021-03-31 was $639.00K.
  • INFUSYSTEM HOLDINGS, INC business acquisition, pro forma net income (loss) for fiscal 2021 was $1.94M, a 88.27% decline from fiscal 2020.
  • INFUSYSTEM HOLDINGS, INC business acquisition, pro forma net income (loss) for fiscal 2020 was $16.50M.
Period endBusiness Acquisition, Pro Forma Net Income (Loss) 3 monthBusiness Acquisition, Pro Forma Net Income (Loss) 6 monthBusiness Acquisition, Pro Forma Net Income (Loss) 6 month as first filedBusiness Acquisition, Pro Forma Net Income (Loss) 9 monthBusiness Acquisition, Pro Forma Net Income (Loss) 12 month
2021-12-31$668.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16
$295.00K
derived: sum of 2 quarters · filed 2023-03-16
$1.30M
derived: sum of 3 quarters · filed 2023-03-16
$1.94M
10-K · filed 2023-03-16
2021-09-30-$373.00K
10-Q · filed 2022-11-08
$628.00K
derived: sum of 2 quarters · filed 2022-11-08
$1.27M
10-Q · filed 2022-11-08
$11.64M
derived: sum of 4 quarters · filed 2023-03-16
2021-06-30$1.00M
10-Q · filed 2022-08-04
$1.64M
10-Q · filed 2022-08-04
$990.00K
10-Q · filed 2021-08-12
$12.02M
derived: sum of 3 quarters · filed 2023-03-16
$14.71M
derived: sum of 4 quarters · filed 2023-03-16
2021-03-31$639.00K
10-Q · filed 2022-05-05
$11.02M
derived: sum of 2 quarters · filed 2023-03-16
$13.71M
derived: sum of 3 quarters · filed 2023-03-16
$17.45M
derived: sum of 4 quarters · filed 2023-03-16
2020-12-31$10.38M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16
$13.07M
derived: sum of 2 quarters · filed 2023-03-16
$16.81M
derived: sum of 3 quarters · filed 2023-03-16
$16.50M
10-K · filed 2023-03-16
2020-09-30$2.69M
10-Q · filed 2021-11-15
$6.43M
derived: sum of 2 quarters · filed 2021-11-15
$6.12M
10-Q · filed 2021-11-15
2020-06-30$3.74M
10-Q · filed 2021-08-12
$3.49M
10-Q · filed 2021-08-12
2015-09-30$1.37M
10-Q · filed 2015-11-12
$2.20M
derived: sum of 2 quarters · filed 2015-11-12
$1.95M
10-Q · filed 2015-11-12
2015-06-30$829.00K
10-Q · filed 2015-08-13
$575.00K
10-Q · filed 2015-08-13
2014-09-30$998.00K
10-Q · filed 2015-11-12
$2.02M
derived: sum of 2 quarters · filed 2015-11-12
$2.76M
10-Q · filed 2015-11-12
2014-06-30$1.02M
10-Q · filed 2015-08-13
$1.75M
10-Q · filed 2015-08-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
UTAH MEDICAL PRODUCTS INC (UTMD)United States$0.238B20.93
Anika Therapeutics, Inc. (ANIK)United States$0.272B-51.71
ORASURE TECHNOLOGIES INC (OSUR)United States$0.272B-6.26
PRO DEX INC (PDEX)United States$0.234B13.64
Cytosorbents Corp (CTSO)United States$0.274B-1.29
TriSalus Life Sciences, Inc. (TLSI)United States$0.283B-9.92
Neuronetics, Inc. (STIM)United States$0.216B-3.25
Mobia Medical, Inc. (MOBI)United States$0.293B
TREACE MEDICAL CONCEPTS, INC. (TMCI)United States$0.297B-4.32
Profound Medical Corp. (PROF)$0.206B-7.37